NCT02799771

Completed

HYPID (Pulmonary Hypertension in Interstitial Lung Disease) ...

Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires Source

Compare

Other study identifiers

Sponsor study identifier

GERMOP- 005

Study Type

observational

Actual enrollment (reported)

210

Locations

1 country

Sites

1

Timeline

Study Start

February 2013

Actual (reported)

Primary Completion

February 2018

Actual (reported)

Study Completion

February 2022

Actual (reported)

Brief Summary

HYPID-2 study is an extension of HYPID study (NCT01443598) : HYPID-2 is also an observational and prospective study of patients with interstitial lung disease and pre capillary hypertension diagnosed by right heart sided catheterization. It concerns only incident patients (i.e patients included within 6 months after PH diagnosis) whereas HYPID concerned prevalent and incident cases. The primary aim is the same than HYPID : identify prognostic factors

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 210 participants
Study completion date: February 2022
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
February 2013
Actual (reported)
First Submitted
June 6, 2016
Actual (reported)
First Posted
June 15, 2016
Actual (reported)
Primary Completion
February 2018
Actual (reported)
Study Completion
February 2022
Actual (reported)

Last Updated: August 3, 2022
Status Verified: August 2022
Last Update Submitted: August 2, 2022

Conditions

Diffuse Interstitial Lung Disease Pulmonary Arterial Hypertension

Keywords

Pulmonary arterial hypertensionInterstitial lung disease at HRCT

Outcome Measures

Primary Outcomes (1)

Overall survival
Determine predictive factors of mortality
2 years

Secondary Outcomes (2)

Progression-free survival
2 years
Response to therapy
2 years

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Incident patients with pre capillary pulmonary hypertension and interstitial lung disease at HRCT

You may qualify if:

Patients newly diagnosed with:

Sponsors & Collaborators

Hospices Civils de Lyon
Othercollaborator
Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires
Otherlead

Study Sites (1)

Louis Pradel Hospital (Bâtiment A4)

Lyon, Bron, 69677, France

Biospecimen

Retention: SAMPLES WITH DNA

Whole blood

MeSH Terms

Conditions

Pulmonary Arterial Hypertension

Condition Hierarchy (Ancestors)

Hypertension, PulmonaryLung DiseasesRespiratory Tract Diseases

Study Officials

Vincent COTTIN, MD
Hospices civils de Lyon / Université Lyon I
PRINCIPAL INVESTIGATOR

Enrollment

210 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Professor Vincent COTTIN

Study Record Dates

First Submitted

June 6, 2016

First Posted

June 15, 2016

Study Start

February 2013

Actual (reported)

NCT02579954

Cardiac Function and Exercise Capacity in Pulmonary Arterial Hypertension

Not ApplicableCompleted

NCT01600898

Screening of Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers

Completed

NCT02525926

Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension

Not ApplicableTerminated

NCT01352026

Evaluation of Metformin Activity in Addition to Conventional Treatment of Grade II or III Pulmonary Arterial Hypertension (PAH)

Phase 2Withdrawn

NCT02968901

Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)

Phase 4Terminated

NCT01484431

A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension

Phase 1/2Completed

Pre capillary pulmonary hypertension at right heart sided catheterization with: mPAP \> or = 25 mmHg, PCWP \< or = 15 mmHg

Interstitial lung disease with diffuse infiltrative opacities on chest CT scan

You may not qualify if:

Pulmonary hypertension related to a thromboembolic disease
Respiratory disease other than diffuse interstitial lung disease
Any etiological factor of pulmonary arterial hypertension based on NICE 2013 classification other than diffuse interstitial lung disease
Any progressive disease associated to a life expectancy less than 6 months other than pulmonary hypertension, diffuse interstitial lung disease and respiratory insufficiency

Contact the study team to confirm eligibility.

Primary Completion

February 2018

Actual (reported)

Study Completion

February 2022

Actual (reported)

Last Updated

August 3, 2022

Record last verified: 2022-08

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT02799771
Data provider: ClinicalTrials.gov
Source updated: 2022-08-03
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:39:22 UTC

Locations

FR(1)

HYPID (Pulmonary Hypertension in Interstitial Lung Disease) EXTENSION

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations